SEC Form 4 · accession 0001127602-17-026760
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R Meyers
Officer — EVP Worldwide Commercial Ops
Period of report
Aug 15, 2017
Accepted (ET)
Aug 31, 2017 · 1:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 15, 2017 | A | 115 | $59.7635 | A | 2,830 | D | |
| Common StockF2 | Aug 15, 2017 | G | 115 | $0.00 | D | 2,715 | D | |
| Common StockF2 | Aug 15, 2017 | G | 115 | $0.00 | A | 126,145 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
- F2Shares gifted to family trust.